 |
市场调查报告书
商品编码
1567134
多发性硬化症药物市场：依药物类别、给药途径、分销管道和地区Multiple Sclerosis Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
预计2024年全球多发性硬化症药物市场规模为301.2亿美元，预计2031年将达395.5亿美元，2024年至2031年复合年增长率为4%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年 | 2023年 | 2024年市场规模 | 301.2亿美元 |
| 实际资料 | 2019-2023 | 预测期 | 2024年至2031年 |
| 预测 2024-2031 年复合年增长率： | 4.00% | 2031年价值预测 | 395.5亿美元 |
多发性硬化症 (MS) 是一种影响中枢神经系统 (CNS) 的慢性自体免疫疾病。当免疫系统攻击髓磷脂（中枢神经系统 (CNS) 中神经纤维周围的保护鞘）时，就会发生多发性硬化症。结果，大脑和身体其他部位之间的讯息传输受到损害。症状可轻可重，取决于中枢神经系统病变的数量和位置。常见症状包括疲劳、四肢无力或麻木、协调性和平衡性下降、视力问题和认知功能障碍。儘管多发性硬化症尚无确定的治疗方法，但干扰素、醋酸Glatiramer雷、单株抗体和皮质类固醇等药物可以抑制症状并减缓疾病的进展。
市场动态：
全球多发性硬化症药物市场的成长是由已开发国家和新兴国家多发性硬化症盛行率不断上升、老年人口不断增加以及多发性硬化症新疗法和创新治疗方法等因素推动的，这些因素包括强大的产品线、快速成长的医疗保健等。然而，与多发性硬化症药物相关的高成本可能会阻碍市场成长。用于多发性硬化症治疗的个人化药物的出现，越来越多地采用联合治疗、输液疗法和口服药物来治疗多发性硬化症，可以为市场成长提供机会。
本研究的主要特点
本报告对全球多发性硬化症治疗药物市场进行了详细分析，包括年复合成长率（CAGR%）。已发布。
它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
根据公司亮点、产品系列、主要亮点、业绩和策略等参数对全球多发性硬化症药物市场的主要企业进行了分析。
主要企业包括百健（Biogen）、诺华（Novartis）、默克（Merck）、赛诺菲（Sanofi）、梯瓦製药（Teva Pharmaceuticals）、拜耳（Bayer）、ACORDA THERAPEUTICS、CELGENE 等。
该报告的见解使负责人和公司经营团队能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球多发性硬化症药物市场报告迎合了该行业的各种相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球多发性硬化症治疗药物市场的各种策略矩阵，将有助于相关人员做出决策。
目录
第一章 研究目的与前提
- 研究目的
- 先决条件
- 简称
第二章 市场展望
- 报告说明
- 市场定义和范围
- 执行摘要
第三章 市场动态、法规与趋势分析
- 市场动态
- 影响分析
- 主要亮点
- 监管场景
- 产品发布/核准
- PEST分析
- 波特分析
- 併购场景
第四章 全球多发性硬化症药物市场，依药物类别，2019-2031 年（十亿美元）
- β干扰素
- 皮质类固醇
- 单株抗体
- 抗肿瘤剂
- 其他的
第五章全球多发性硬化症药物市场，依给药途径，2019-2031 年（十亿美元）
- 口服
- 注射
- 其他的
第六章 2019-2031 年全球多发性硬化症药物市场（按分销管道）（十亿美元）
- 医院药房
- 零售药房
- 网路药房
第七章2019-2031年全球多发性硬化症药物市场（按地区）（十亿美元）
- 北美洲
- 拉丁美洲
- 欧洲
- 亚太地区
- 中东
- 非洲
第八章 竞争格局
- Biogen Inc.
- Novartis AG
- Merck KGaA
- Sanofi SA
- Acorda Therapeutics, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bristol-Myers Squibb Company
- Bayer AG
- F.Hoffmann-La Roche AG
- Viatris Inc.（Mylan NV）
- Johnson & Johnson
- EMD Serono, Inc.
- TG Therapeutics, Inc.
- Genentech, Inc.
- Celgene Corporation
- AbbVie Inc.
- Amgen Inc.
- UCB SA
- Sandoz（a Novartis division）
- Ipsen SA
第九章 分析师建议
- Wheel of Fortune
- 分析师观点
- Coherent Opportunity Map
第10章 参考文献与调查方法
- 参考
- 调查方法
- 关于出版商
Global multiple sclerosis therapeutics market is estimated to be valued at USD 30.12 Billion in 2024 and is expected to reach USD 39.55 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 4% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 30.12 Bn |
| Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
| Forecast Period 2024 to 2031 CAGR: | 4.00% | 2031 Value Projection: | US$ 39.55 Bn |
Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS). It is caused when the immune system attacks myelin, the protective sheath surrounding nerve fibers of the CNS. The damage disrupts communication between the brain and other parts of the body. Symptoms can be mild or severe, depending on the number and location of lesions in the CNS. Common symptoms include fatigue, weakness or numbness in the limbs, poor coordination and balance, vision problems, and cognitive dysfunction. There has been no known cure for MS but medications such as interferons, glatiramer acetate, monoclonal antibodies, corticosteroids can manage the disease symptoms and slow down its progression.
Market Dynamics:
Global multiple sclerosis therapeutics market growth is driven by factors like increasing prevalence of multiple sclerosis across both developed and developing nations, growing geriatric population, robust pipeline of new and innovative treatment therapies for multiple sclerosis, surging healthcare spending, and availability of reimbursement schemes. However, high costs associated with multiple sclerosis drugs can hamper the market growth. Emergence of personalized medicines for multiple sclerosis treatment, growing adoption of combination therapies, infusion therapies, and oral drugs for multiple sclerosis treatment can offer market growth opportunities.
Key features of the study:
This report provides in-depth analysis of the global multiple sclerosis therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global multiple sclerosis therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen, Novartis, Merck, Sanofi, Teva Pharmaceuticals, Bayer, ACORDA THERAPEUTICS and CELGENE
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global multiple sclerosis therapeutics market
Detailed Segmentation-
- By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agent
- Others
- By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
- Oral
- Injection
- Others
- By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Bn, 2019 - 2031)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Biogen Inc.
- Novartis AG
- Merck KGaA
- Sanofi S. A.
- Acorda Therapeutics, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bristol-Myers Squibb Company
- Bayer AG
- Hoffmann-La Roche AG
- Viatris Inc. (Mylan NV)
- Johnson & Johnson
- EMD Serono, Inc.
- TG Therapeutics, Inc.
- Genentech, Inc.
- Celgene Corporation
- AbbVie Inc.
- Amgen Inc.
- UCB S.A.
- Sandoz (a Novartis division)
- Ipsen S.A.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Multiple Sclerosis Therapeutics Market, By Drug Class
- Global Multiple Sclerosis Therapeutics Market, By Route of Administration
- Global Multiple Sclerosis Therapeutics Market, By Distribution Channel
- Global Multiple Sclerosis Therapeutics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Beta Interferon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Antineoplastic Agent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020- 2031
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2019-2031, (USD Bn)
- Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Multiple Sclerosis Therapeutics Market, By Region, 2019 - 2031, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2020 - 2031, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S. A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Acorda Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceuticals Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- F.Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc. (Mylan NV)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- EMD Serono, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- TG Therapeutics, Inc.
- Genentech, Inc.
- Celgene Corporation
- AbbVie Inc.
- Amgen Inc.
- UCB S.A.
- Sandoz (a Novartis division)
- Ipsen S.A.
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
多发性硬化症药物市场占有率及趋势分析报告：2024-2030 年按药物类别、给药途径、分销管道、地区和细分市场预测
2024-2032 年按药物、药物类型、给药途径、配销通路和地区分類的多发性硬化症治疗市场报告
全球多发性硬化症市场评估：依 MS 类型、药物类别、诊断、给药途径、最终用户、地区、机会、预测（2017-2031 年）
全球多发性硬化症治疗药物市场规模、份额、成长分析、按药物类型、给药途径- 2023-2030 年产业预测
多发性硬化症市场、份额、规模、趋势、产业分析报告：按药物类型、给药途径、地区、细分市场预测，2024-2032 年
多发性硬化症市场:KOL的洞察
多发性硬化症市场：按治疗方法（注射、口服）、按用途（医院、研究）分类 - 全球预测 2023-2030
多发性硬化症治疗全球市场规模研究与预测：按药物类别、给药途径、分销渠道和地区分析，2022-2029 年
多发性硬化症治疗的全球市场
原发性进行性多发性硬化症治疗药的全球市场 (2022-2031年):药物类型 (已通过核准药·开发平台药物)·流通管道 (零售药局·电子商务) 别市场规模·占有率·成长·趋势·预测